<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following risk factors which could affect", fill: "#f0e68c"},
{source: "1: following risk factors which could affect", target: "1: financial condition", fill: "#f0e68c"},
{source: "1: financial condition", target: "1: operations", fill: "#f0e68c"},
{source: "1: following risk factors which could affect", target: "6: Widespread ", fill: "#79443b"},
{source: "6: Widespread ", target: "6: acceptance would represent", fill: "#79443b"},
{source: "6: acceptance would represent", target: "6: significant", fill: "#79443b"},
{source: "6: significant", target: "6: medical practice patterns", fill: "#79443b"},
{source: "6: Widespread ", target: "7: professionals", fill: "#fb9902"},
{source: "7: professionals", target: "7: limitations", fill: "#fb9902"},
{source: "7: professionals", target: "18: targeted international markets through", fill: "#e75480"},
{source: "18: targeted international markets through", target: "18: strategic alliance with", fill: "#e75480"},
{source: "18: strategic alliance with", target: "18: regional distributors", fill: "#e75480"},
{source: "18: regional distributors", target: "18: market through", fill: "#e75480"},
{source: "18: market through", target: "18: direct sales force", fill: "#e75480"},
{source: "18: direct sales force", target: "18: several regional", fill: "#e75480"},
{source: "18: several regional", target: "18: national distributors", fill: "#e75480"},
{source: "18: targeted international markets through", target: "27: Potential ", fill: "#a8e4a0"},
{source: "27: Potential ", target: "27: acquisition", fill: "#a8e4a0"},
{source: "27: acquisition", target: "27: assimilating", fill: "#a8e4a0"},
{source: "27: assimilating", target: "27: technologies", fill: "#a8e4a0"},
{source: "27: technologies", target: "27: operations", fill: "#a8e4a0"},
{source: "27: operations", target: "27: unanticipated", fill: "#a8e4a0"},
{source: "27: unanticipated", target: "27: accounting", fill: "#a8e4a0"},
{source: "27: accounting", target: "27: transaction", fill: "#a8e4a0"},
{source: "27: transaction", target: "27: implementing", fill: "#a8e4a0"},
{source: "27: implementing", target: "27: managements", fill: "#a8e4a0"},
{source: "27: managements", target: "27: relationships", fill: "#a8e4a0"},
{source: "27: relationships", target: "27: potential loss", fill: "#a8e4a0"},
{source: "27: potential loss", target: "27: key employees", fill: "#a8e4a0"},
{source: "27: key employees", target: "27: organizations", fill: "#a8e4a0"},
{source: "27: Potential ", target: "29: finance acquisitions by incurring debt", fill: "#f0f8ff"},
{source: "29: finance acquisitions by incurring debt", target: "29: existing shareholders would", fill: "#f0f8ff"},
{source: "29: existing shareholders would", target: "29: generate additional profits", fill: "#f0f8ff"},
{source: "29: generate additional profits", target: "29: interest expense", fill: "#f0f8ff"},
{source: "29: finance acquisitions by incurring debt", target: "31: cease amortization", fill: "#fff"},
{source: "31: cease amortization", target: "31: intangible assets", fill: "#fff"},
{source: "31: intangible assets", target: "31: indefinite lives", fill: "#fff"},
{source: "31: indefinite lives", target: "31: method testing", fill: "#fff"},
{source: "31: method testing", target: "31: impairment on", fill: "#fff"},
{source: "31: impairment on", target: "31: certain events", fill: "#fff"},
{source: "31: certain events", target: "31: circumstances", fill: "#fff"},
{source: "31: circumstances", target: "31: fair value", fill: "#fff"},
{source: "31: fair value", target: "31: intangible assets with indefinite lives falls", fill: "#fff"},
{source: "31: cease amortization", target: "47: Technological ", fill: "#ff033e"},
{source: "47: Technological ", target: "47: difficult", fill: "#ff033e"},
{source: "47: difficult", target: "47: new product transitions", fill: "#ff033e"},
{source: "47: Technological ", target: "48: future products will", fill: "#00416a"},
{source: "48: future products will", target: "48: development efforts", fill: "#00416a"},
{source: "48: development efforts", target: "48: compliance with governmental clearance", fill: "#00416a"},
{source: "48: compliance with governmental clearance", target: "48: approval requirements", fill: "#00416a"},
{source: "48: future products will", target: "49: may encounter unforeseen technological", fill: "#fefe22"},
{source: "49: may encounter unforeseen technological", target: "49: scientific problems", fill: "#fefe22"},
{source: "49: scientific problems", target: "49: force abandonment", fill: "#fefe22"},
{source: "49: force abandonment", target: "49: development", fill: "#fefe22"},
{source: "49: development", target: "49: specific product", fill: "#fefe22"},
{source: "49: may encounter unforeseen technological", target: "59: recent periods", fill: "#fbcce7"},
{source: "59: recent periods", target: "59: employee stock options", fill: "#fbcce7"},
{source: "59: employee stock options", target: "59: exercise prices", fill: "#fbcce7"},
{source: "59: exercise prices", target: "59: stock price which reduces", fill: "#fbcce7"},
{source: "59: stock price which reduces", target: "59: could affect", fill: "#fbcce7"},
{source: "59: could affect", target: "59: attract present", fill: "#fbcce7"},
{source: "59: recent periods", target: "133: outstanding common stock", fill: "#4b5320"},
{source: "133: outstanding common stock", target: "133: of the Medis ", fill: "#4b5320"},
{source: "133: of the Medis ", target: "133: Ilmenau Germany", fill: "#4b5320"},
{source: "133: outstanding common stock", target: "163: common stock", fill: "#eee8aa"},
{source: "163: common stock", target: "163: price volatility", fill: "#eee8aa"},
{source: "163: common stock", target: "START_HERE", fill: "#eee8aa"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CARDIODYNAMICS INTERNATIONAL CORP      ITEM 1A RISK FACTORS          In addition to the other information contained in this Form 10-K, you should     consider  the  <font color="blue">following risk <font color="blue">factors which</font> <font color="blue">could affect</font></font> our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend upon on</font> our BioZ <font color="blue">product line</font>, which is in its <font color="blue">early stages</font> of     <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Our  future is <font color="blue">dependent upon</font> the success of the BioZ <font color="blue">product line</font> and     similar products that are <font color="blue">based on</font> the <font color="blue">same core <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>The market for     these products is in a <font color="blue">relatively early stage</font> of <font color="blue">development</font> and may never     fully develop as we expect</td>
    </tr>
    <tr>
      <td>The long-term commercial success of the <font color="blue">BioZ     </font>product  line  requires <font color="blue">widespread <font color="blue">acceptance</font></font> of our <font color="blue">products as safe</font>,     <font color="blue">efficient</font>  and cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Widespread </font><font color="blue"><font color="blue">acceptance</font> would represent</font> a     <font color="blue">significant</font> change in <font color="blue">medical practice patterns</font></td>
    </tr>
    <tr>
      <td>In the past, some medical     <font color="blue">professionals</font> have hesitated to use ICG products because of <font color="blue">limitations</font>     experienced with older, analog-based monitors</td>
    </tr>
    <tr>
      <td>Invasive procedures, such as     PAC, are <font color="blue"><font color="blue">generally</font> accepted</font> in the <font color="blue">medical <font color="blue">community</font></font> and have a <font color="blue">long history</font>     of use</td>
    </tr>
    <tr>
      <td>We have sponsored and intend to continue to sponsor or <font color="blue">support clinical</font>     trials</td>
    </tr>
    <tr>
      <td>We cannot be certain that <font color="blue">clinical trials will</font> be completed, that     they will have a positive outcome or that a positive outcome in these trials     will be sufficient to promote <font color="blue">widespread <font color="blue">acceptance</font></font> of our <font color="blue">products within</font>     the <font color="blue">medical <font color="blue">community</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part upon the <font color="blue">availability</font> of adequate third-party     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>Our  success  will  depend  in  part  on  the <font color="blue">availability</font> of adequate     <font color="blue">reimbursement</font> for our customers from third-party healthcare payers, such as     Medicare,  private  health  insurers  and  <font color="blue">managed care <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">payers increasingly</font> are <font color="blue">challenging</font> the pricing of medical     products and services</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>may not be at, or remain at, price     <font color="blue">levels adequate</font> to allow medical <font color="blue">professionals</font> to realize an <font color="blue">appropriate</font>     return on the purchase of our products</td>
    </tr>
    <tr>
      <td>In addition, third-party payers may     not cover all or a portion of the cost of our products and related services,     or they may place <font color="blue">significant</font> <font color="blue">restrictions</font> on the <font color="blue">circumstances</font> in which     <font color="blue">coverage will</font> be available</td>
    </tr>
    <tr>
      <td><font color="blue">In January </font>2004, CMS issued an <font color="blue">updated national</font>     <font color="blue">coverage determination which served</font> to restrict the number of <font color="blue">hypertensive</font>     <font color="blue">patients eligible</font> for Medicare <font color="blue">reimbursement</font> for ICG monitoring</td>
    </tr>
    <tr>
      <td>We must maintain and develop <font color="blue">strategic <font color="blue">relationships</font> with <font color="blue">third parties</font></font> to     <font color="blue">increase market penetration</font> of our <font color="blue">product line</font>s</td>
    </tr>
    <tr>
      <td>We distribute our products to <font color="blue">targeted <font color="blue">international</font> markets through</font> our     <font color="blue">strategic alliance with</font> GEMS-IT and a network of <font color="blue">regional <font color="blue">distributors</font></font> and     to the US <font color="blue">market through</font> our <font color="blue">direct sales force</font> and <font color="blue">several regional</font> and     <font color="blue">national <font color="blue">distributors</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may enter into</font> similar <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> other     companies and <font color="blue">establish <font color="blue">technology</font> partnerships with</font> other <font color="blue">medical product</font>,     <font color="blue">distribution</font> and <font color="blue"><font color="blue">technology</font> companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successfully </font>managing the <font color="blue">interaction</font>     of our <font color="blue">direct sales force</font> and strategic <font color="blue">distribution</font> partners is a complex     process</td>
    </tr>
    <tr>
      <td>Moreover, since each <font color="blue">distribution</font> method has <font color="blue">distinct risks</font>, gross     margins and <font color="blue">operation costs</font>, our failure to implement and maintain the most     <font color="blue">advantageous balance</font> in the <font color="blue">delivery model</font> for our <font color="blue">products could adversely</font>     affect our revenues, gross margins and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Widespread </font><font color="blue">acceptance</font>     of our BioZ <font color="blue">products may</font> be <font color="blue">dependent on</font> our <font color="blue">establishing</font> and maintaining     these <font color="blue">strategic <font color="blue">relationships</font> with <font color="blue">third parties</font></font> and on the successful     <font color="blue">distribution</font> efforts of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Many aspects of our <font color="blue">relationships</font> with <font color="blue">third parties</font>, and the <font color="blue">success with</font>     which <font color="blue">third parties</font> promote <font color="blue">distribution</font> of our products, are beyond our     control</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in maintaining our <font color="blue">existing strategic</font>     <font color="blue">relationships</font> and in identifying and <font color="blue">entering into future <font color="blue">development</font></font> and     <font color="blue">distribution</font> <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may not be able to make <font color="blue">future <font color="blue"><font color="blue">acquisition</font>s</font></font> or <font color="blue">successfully integrate</font> our     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>As  part  of  our  growth  strategy,  we  intend to continue to pursue     <font color="blue">opportunities</font> to acquire or make <font color="blue">investments</font> in other <font color="blue">technologies</font>, products     and <font color="blue">businesses</font> that <font color="blue">could enhance</font> our technical capabilities, complement our     <font color="blue">current products</font> or expand the breadth of our markets or <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       <font color="blue">Potential </font>and completed <font color="blue"><font color="blue">acquisition</font>s</font> and strategic <font color="blue">investments</font> involve     numerous risks, including:           •   problems <font color="blue">assimilating</font> the purchased <font color="blue">technologies</font>, products or business     <font color="blue">operations</font>;           •   <font color="blue">unanticipated</font> cost associated with the <font color="blue">acquisition</font>, including     <font color="blue">accounting</font> charges and <font color="blue">transaction</font> expenses;           •   problems <font color="blue">implementing</font> and maintaining adequate standards, procedures,     controls and policies;           •   diversion of management’s attention from our core business;           •   adverse effects on existing business <font color="blue">relationships</font> with suppliers and     customers;           •   risks associated with entering markets in which we have no or limited     prior experience; and           •   <font color="blue">potential loss</font> of <font color="blue">key employees</font> of acquired <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">properly evaluate</font> and execute <font color="blue"><font color="blue">acquisition</font>s</font> and strategic     <font color="blue">investments</font>, our <font color="blue">management team may</font> be <font color="blue">distracted from</font> our day-to-day     <font color="blue">operations</font>, our business may be disrupted, and our operating results may     suffer</td>
    </tr>
    <tr>
      <td>In addition, if we finance <font color="blue"><font color="blue">acquisition</font>s</font> by incurring debt or issuing     equity, our <font color="blue">existing shareholders would</font> be diluted or we would have to     <font color="blue">generate <font color="blue">additional</font> profits</font> to cover the <font color="blue">interest expense</font></td>
    </tr>
    <tr>
      <td>Our  future  financial  results  could  be <font color="blue">adversely impacted by asset</font>     <font color="blue">impairments</font> or other charges</td>
    </tr>
    <tr>
      <td>Statement of Financial Accounting Standards Nodtta 142, “Goodwill and <font color="blue">Other     </font>Intangible Assets” requires that we <font color="blue">cease <font color="blue">amortization</font></font> of goodwill and other     <font color="blue">intangible assets</font> determined to have <font color="blue">inde<font color="blue">finite lives</font></font>, and establish a     <font color="blue">method testing</font> these assets for <font color="blue">impairment on</font> an annual or on an interim     basis if <font color="blue">certain events</font> occur or <font color="blue">circumstances</font> change that would reduce the     <font color="blue">fair value</font> of a reporting unit below its carrying value or if the <font color="blue">fair value</font>     of <font color="blue">intangible assets</font> with <font color="blue">inde<font color="blue">finite lives</font></font> falls below their carrying value</td>
    </tr>
    <tr>
      <td>We  evaluate  intangible  assets  determined  to have <font color="blue">finite lives</font> for     <font color="blue">recoverability whenever events</font> or changes in <font color="blue">circumstances</font> indicate that     their carrying <font color="blue">amounts may</font> not be recoverable</td>
    </tr>
    <tr>
      <td>These events or <font color="blue">circumstances</font>     could include a <font color="blue">significant</font> change in the business climate, legal factors,     operating performance indicators, <font color="blue">competition</font>, sales or <font color="blue">disposition</font> of a     <font color="blue">significant</font> portion of the business, or other <font color="blue">factors such as</font> a decline in     our <font color="blue">market value</font> below our book value for an <font color="blue">extended period</font> of time</td>
    </tr>
    <tr>
      <td>In the     case of <font color="blue">intangible assets</font> with <font color="blue">inde<font color="blue">finite lives</font></font>, we evaluate whether events     or <font color="blue">circumstances</font> continue to support an <font color="blue">indefinite</font> useful life</td>
    </tr>
    <tr>
      <td>We <font color="blue">also evaluate</font> the estimated lives of all <font color="blue">intangible assets</font> on an annual     basis, including those with <font color="blue">inde<font color="blue">finite lives</font></font>, to determine if events and     <font color="blue">circumstances</font> continue to support an <font color="blue">indefinite</font> useful life or the remaining     useful life, as applicable, or if a revision in the <font color="blue">remaining period</font> of     <font color="blue">amortization</font>  is  required</td>
    </tr>
    <tr>
      <td>The  amount of any such annual or interim     <font color="blue">impairment charge could</font> be <font color="blue">significant</font>, and could have a material adverse     effect on reported financial results for the period in which the charge is     taken</td>
    </tr>
    <tr>
      <td><font color="blue">Utilization </font>of our <font color="blue"><font color="blue">deferred tax</font> assets</font> may be limited and is <font color="blue">dependant</font> on     future taxable income</td>
    </tr>
    <tr>
      <td>We have federal operating <font color="blue">loss <font color="blue">carryforwards</font></font> of approximately dlra28cmam400cmam000     for  federal  <font color="blue">income tax purposes</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Tax Reform Act </font>of 1986 contains     provisions under section 382 <font color="blue">of the Internal Revenue Code </font>that limit the     <font color="blue">federal net</font> operating <font color="blue">loss <font color="blue">carryforwards</font></font> that may be used in any <font color="blue">given year</font>     in the event of <font color="blue">specified occurrences</font>, including <font color="blue">significant</font> ownership     changes</td>
    </tr>
    <tr>
      <td>If these <font color="blue">specified events</font> occur we may lose some or all of the tax     benefits of these <font color="blue">carryforwards</font></td>
    </tr>
    <tr>
      <td>We  determined,  <font color="blue">based on</font> our <font color="blue">assessment</font> of both positive and negative     evidence  and  objective  and  subjective  evidence,  which takes into     <font color="blue">consideration</font> our forecasted taxable income, that it is more <font color="blue">likely than</font> not     that we <font color="blue">will benefit from</font> the use of the <font color="blue"><font color="blue">deferred tax</font> assets</font>, and therefore     we reduced our <font color="blue"><font color="blue">valuation allowance</font> on</font> the existing <font color="blue"><font color="blue">deferred tax</font> assets</font>     related to these NOL’s to zero in the <font color="blue">fourth quarter</font> of fiscal 2004 as     required by SFAS Nodtta 109 “<font color="blue">Accounting for Income Taxes</font>”</td>
    </tr>
    <tr>
      <td>Upon reducing the     <font color="blue">valuation allowance</font> and recognizing the                                           17     ______________________________________________________________________       <font color="blue"><font color="blue">deferred tax</font> assets</font>, we recognized the tax benefit of <font color="blue"><font color="blue">deferred tax</font> assets</font></td>
    </tr>
    <tr>
      <td>The favorable impact of the <font color="blue">tax benefit distorts</font> the trends in our operating     results and impacts the <font color="blue">comparability</font> of our <font color="blue">current period</font> results of     <font color="blue">operations</font> with other periods</td>
    </tr>
    <tr>
      <td><font color="blue">At November </font>30, 2005, in light of recent     losses, we determined, <font color="blue">based on</font> our <font color="blue">assessment</font> of both positive and negative     evidence  and  objective  and  subjective  evidence,  which takes into     <font color="blue">consideration</font> our forecasted taxable income, that it is more <font color="blue">likely than</font> not     that we will not realize all or a portion of the <font color="blue"><font color="blue">deferred tax</font> assets</font>, and     recorded a <font color="blue">valuation allowance</font> for the full amount of the <font color="blue">deferred tax</font>     assets  which  resulted in <font color="blue">recognition</font> of <font color="blue">income tax expense</font> and lower     earnings  in  2005</td>
    </tr>
    <tr>
      <td>In <font color="blue">calculating</font> our <font color="blue">tax provision</font> and assessing the     likelihood that we will be able to use the <font color="blue"><font color="blue">deferred tax</font> assets</font> we will     continue to evaluate our ability to realize these <font color="blue"><font color="blue">deferred tax</font> assets</font></td>
    </tr>
    <tr>
      <td>As we     <font color="blue">generate taxable income</font> for <font color="blue">book purposes</font>, we will realize the benefit of     the <font color="blue"><font color="blue">deferred tax</font> assets</font> to offset the tax expense associated with pre-tax     income, resulting in a <font color="blue">reduced net tax expense</font> for the period and greater     <font color="blue">net income than would normally</font> be expected</td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font>change is <font color="blue">difficult</font> to predict and <font color="blue">new product transitions</font> are     <font color="blue">difficult</font> to manage</td>
    </tr>
    <tr>
      <td>Our  product  line has required, and any <font color="blue">future products will</font> require,     substantial <font color="blue"><font color="blue">development</font> efforts</font> and <font color="blue"><font color="blue">compliance with</font> <font color="blue">government</font>al clearance</font>     or <font color="blue">approval <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter unforeseen technological</font> or     <font color="blue">scientific problems</font> that <font color="blue">force abandonment</font> or substantial change in the     <font color="blue">development</font> of a <font color="blue">specific product</font> or process</td>
    </tr>
    <tr>
      <td>In addition, as we introduce     <font color="blue">new products</font> and <font color="blue">product <font color="blue">enhancements</font></font>, we may not be able to <font color="blue"><font color="blue">effective</font>ly</font>     segregate or transition from <font color="blue">existing products</font> <font color="blue">which could</font> negatively impact     revenue, gross margin and overall <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Among the risks associated     with  the  <font color="blue">introduction</font>  of  <font color="blue">new products</font> are delays in <font color="blue">development</font> or     <font color="blue">manufacturing</font>,  <font color="blue">variations</font>  in  cost,  delays in customer purchases in     <font color="blue">anticipation</font> of new <font color="blue"><font color="blue">introduction</font>s</font>, <font color="blue">difficult</font>y in predicting customer demand     for the new and <font color="blue">existing offerings</font> and <font color="blue"><font color="blue">effective</font>ly</font> managing inventory levels     and  the  risks  that  new <font color="blue">products may</font> have quality or other defects</td>
    </tr>
    <tr>
      <td>Furthermore, sales of our new <font color="blue">products may</font> replace sales, or result in     <font color="blue">discounting</font> of our <font color="blue">current offerings</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on management</font> and other <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">dependent on</font> a limited number of <font color="blue">key management</font> and technical     personnel</td>
    </tr>
    <tr>
      <td>The  loss of one or more of our <font color="blue">key employees</font> may hurt our     business if we are unable to identify other <font color="blue">individuals</font> to <font color="blue">provide us with</font>     similar services</td>
    </tr>
    <tr>
      <td>We do not maintain “key person” <font color="blue">insurance on</font> any of our     employees</td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense <font color="blue">competition</font></font> in our <font color="blue">recruiting <font color="blue">activities</font></font> and may not be able     to attract or retain <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">historically used stock</font>     <font color="blue">options as key <font color="blue">components</font></font> of our <font color="blue">total employee compensation program</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">recent periods</font>, many of our <font color="blue">employee <font color="blue">stock options</font></font> have had <font color="blue">exercise prices</font>     in excess of our stock price, which reduces their value to employees and     <font color="blue">could affect</font> our ability to retain and <font color="blue">attract present</font> and prospective     employees</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">implementation</font> of FAS 123R will require us to     record a charge to earnings for <font color="blue"><font color="blue">employee stock</font> option grants</font> and other     <font color="blue">equity incentives which will</font> change our <font color="blue">compensation strategy</font></td>
    </tr>
    <tr>
      <td>Our ability     to retain our <font color="blue">existing personnel</font> and <font color="blue">attract <font color="blue">additional</font> highly qualified</font>     <font color="blue">personnel will impact</font> our <font color="blue">future success</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">stock exchange</font> and <font color="blue"><font color="blue">government</font> regulation</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 and recent SEC and <font color="blue">stock exchange</font> <font color="blue">regulations</font>     have increased financial reporting and <font color="blue">disclosure</font> <font color="blue">requirements</font>, corporate     governance and internal control <font color="blue">requirements</font>, including compliance of our     acquired <font color="blue">businesses</font> that have <font color="blue">significant</font>ly increased the <font color="blue">administrative</font>     costs of <font color="blue">documenting</font> and auditing internal processes, gathering data, and     reporting information</td>
    </tr>
    <tr>
      <td>In 2004 and 2005, costs related to <font color="blue">compliance with</font>     these <font color="blue">regulations</font> amounted to approximately dlra500cmam000 and dlra1dtta2 million,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>In addition, the reporting timeframes have <font color="blue">been compressed</font></td>
    </tr>
    <tr>
      <td>The need to commit substantial resources and <font color="blue">management attention</font> in these     areas <font color="blue">could impact</font> our ability to deploy those <font color="blue">same resources</font> to other areas     of our business</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">comply with</font> the <font color="blue">requirements</font>, it could     <font color="blue">significant</font>ly impact our <font color="blue">market valuation</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       We may not have <font color="blue">adequate <font color="blue"><font color="blue">intellectual</font> property</font> protection</font></td>
    </tr>
    <tr>
      <td>Our patents and <font color="blue"><font color="blue">proprietary</font> <font color="blue">technology</font> may</font> not be sufficient to protect our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>In addition, we have received <font color="blue">communications</font>     from <font color="blue">third parties</font> asserting that our ‘754 patent is invalid</td>
    </tr>
    <tr>
      <td>For example,     during 2005, we <font color="blue">became aware</font> of a company that was selling non-FDA cleared     ICG sensors for use with our BioZ systems</td>
    </tr>
    <tr>
      <td>We believe their sensors are in     violation of our patent and have filed a <font color="blue">patent infringement suit</font></td>
    </tr>
    <tr>
      <td>They have     in  turn  <font color="blue">countersued</font> to invalidate the <font color="blue">patent as well as</font> for tortious     interference with contracts, <font color="blue">unlawful tying</font> and <font color="blue">unlawful restraint</font> of trade</td>
    </tr>
    <tr>
      <td>We  intend  to  <font color="blue">vigorously defend against</font> these claims and protect our     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>Any claims resulting in <font color="blue"><font color="blue">intellectual</font> property</font>     litigation, whether defensive or <font color="blue">offensive would</font> have <font color="blue">no certain outcome</font> and     would be costly and time-consuming</td>
    </tr>
    <tr>
      <td>In addition, if our actions to enforce     our patents are found to be a violation of laws related to <font color="blue">unlawful tying</font> or     restraint of trade, we may be required to pay damages to <font color="blue">third parties</font>,     <font color="blue">which could</font> be costly and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>The validity and breadth of claims in <font color="blue">medical <font color="blue">technology</font> patents involve</font>     <font color="blue">complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>There can be no assurance that pending     patent  <font color="blue">applications will</font> result in issued patents, that <font color="blue">future patent</font>     <font color="blue">applications will</font> be issued, that <font color="blue">patents issued</font> to or <font color="blue"><font color="blue">licensed by us</font> will</font>     not be challenged or <font color="blue">circumvented by <font color="blue">competitors</font></font> or that <font color="blue">such patents will</font>     be found to be valid or <font color="blue">sufficiently broad</font> to protect our <font color="blue">technology</font> or to     <font color="blue">provide us with</font> a <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents may</font> be found to be     invalid and other <font color="blue">companies may</font> claim rights in or ownership of the patents     and other <font color="blue"><font color="blue">proprietary</font> rights</font> held or <font color="blue">licensed by us</font></td>
    </tr>
    <tr>
      <td>Also, our existing     <font color="blue">patents may</font> not <font color="blue">cover products</font> that we develop in the future</td>
    </tr>
    <tr>
      <td>Moreover, when     our patents expire, the <font color="blue">inventions will enter</font> the <font color="blue">public domain</font></td>
    </tr>
    <tr>
      <td>We also rely on non<font color="blue">disclosure</font> and non<font color="blue">competition</font> <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> employees,     <font color="blue">consultants</font> and other parties to <font color="blue">protect <font color="blue">trade secrets</font></font> and other <font color="blue">proprietary</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that these <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> will</font> not be     breached, that we will have <font color="blue">adequate remedies</font> for any breach, that others     will not <font color="blue">independently</font> develop equivalent <font color="blue">proprietary</font> information or that     third  <font color="blue">parties will</font> not <font color="blue">otherwise <font color="blue">gain access</font></font> to our <font color="blue">trade secrets</font> and     <font color="blue">proprietary</font> knowledge</td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">competition</font> from</font> other companies and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We  compete  with  other  companies  that are developing and marketing     <font color="blue">noninvasive</font>  <font color="blue">hemodynamic</font>  monitors</td>
    </tr>
    <tr>
      <td>In mid-2004, Analogic released the     LifeGard ICG Monitor, which is <font color="blue">also available</font> to be sold by Philips</td>
    </tr>
    <tr>
      <td>We are     also  subject  to  <font color="blue">competition</font>  from  companies  that <font color="blue">support invasive</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Many of these companies have more established and larger     marketing and sales <font color="blue">organizations</font>, <font color="blue">significant</font>ly greater financial and     technical resources and a <font color="blue">larger <font color="blue">installed base</font></font> of <font color="blue">customers than</font> we do</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">introduction</font> by others</font> of products embodying new <font color="blue">technologies</font> and the     emergence of <font color="blue">new industry standards may</font> render our <font color="blue">products obsolete</font> and     unmarketable</td>
    </tr>
    <tr>
      <td>In addition, other <font color="blue">technologies</font> or <font color="blue">products may</font> be developed     that have an <font color="blue">entirely different approach</font> or means of accomplishing the     <font color="blue">intended purposes</font> of our products</td>
    </tr>
    <tr>
      <td>Accordingly, the life cycles of our     products are <font color="blue">difficult</font> to estimate</td>
    </tr>
    <tr>
      <td>To <font color="blue">compete successfully</font>, we must develop     and introduce <font color="blue">new products</font> that keep <font color="blue">pace with technological advancements</font>,     respond to evolving consumer <font color="blue">requirements</font> and achieve <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>We     may be unable to develop <font color="blue">new products</font> that address our <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Our business plan contemplates an <font color="blue">income stream from sales</font> of disposable     sensors that are <font color="blue">compatible with</font> an <font color="blue">installed base</font> of our monitors</td>
    </tr>
    <tr>
      <td>We may     be  subject to price <font color="blue">competition</font> from other <font color="blue">sensor <font color="blue">manufacturers</font> whose</font>     products are also <font color="blue">compatible with</font> our monitors</td>
    </tr>
    <tr>
      <td>In addition, our current and     potential <font color="blue">competitors</font> may establish cooperative <font color="blue">relationships</font> with large     medical  equipment  companies  to  <font color="blue">gain access</font> to <font color="blue">greater research</font> and     <font color="blue">development</font>  or  marketing  resources</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>may result in price     reductions, reduced gross margins and loss of market share</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       If <font color="blue">market <font color="blue">conditions</font></font> cause us to reduce the <font color="blue">selling price</font> of our products or     sensors, our margins and operating results <font color="blue">will decrease</font></td>
    </tr>
    <tr>
      <td>The  selling  price  of our products and sensors are subject to market     <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Market  <font color="blue">conditions</font> that <font color="blue">could impact</font> these aspects of our     <font color="blue">operations</font> include:           •   Changes in the <font color="blue">reimbursement</font> policies of <font color="blue">government</font> and third-party     payers;           •   Hospital or physician practice <font color="blue">budgetary</font> <font color="blue">constraints</font>;           •   The <font color="blue">introduction</font> of <font color="blue">competing products</font>;           •   Price <font color="blue">reductions by</font> our <font color="blue">competitors</font>;           •   <font color="blue">Development </font>of more <font color="blue">effective</font> products by our <font color="blue">competitors</font>; and           •   <font color="blue">Lengthening </font>of buying or selling cycles;         If  such <font color="blue">conditions</font> force us to sell our products and <font color="blue">systems at lower</font>     prices, or if we are unable to <font color="blue"><font color="blue">effective</font>ly</font> develop and market competitive     products,  our market share, margins and operating results <font color="blue">will likely</font>     decrease</td>
    </tr>
    <tr>
      <td><font color="blue">Effective December </font>1, 2005, we will be required to account for <font color="blue">stock options</font>     under our <font color="blue">employee stock</font> plans as a <font color="blue">compensation expense</font>, our net income and     <font color="blue">earnings per</font> share could be <font color="blue">significant</font>ly reduced</td>
    </tr>
    <tr>
      <td>For <font color="blue">employee option grants</font>, we calculate <font color="blue">compensation expense</font> and disclose     the  impact  on net income (loss) and net income (loss) per share in a     footnote to our <font color="blue">financial statements</font></td>
    </tr>
    <tr>
      <td>Recent <font color="blue">accounting</font> pronouncements will     require us to record <font color="blue">compensation expense</font> for <font color="blue"><font color="blue">employee stock</font> option grants</font>     in our statement of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Note 1, “Stock-Based Compensation,” to our     <font color="blue">financial statements</font>, reflects the impact that adoption of FAS 123 would     have had on our net income (loss) and net income (loss) per share had we     adopted  this  provision  during the <font color="blue">past three years</font></td>
    </tr>
    <tr>
      <td>We have not yet     determined the <font color="blue">specific impact</font> of FAS 123R on future periods</td>
    </tr>
    <tr>
      <td>We have a history of losses and may experience <font color="blue">continued losses</font></td>
    </tr>
    <tr>
      <td>With the exception of 2002 through 2004, we have experienced losses every     year because we have expended more money in the course of <font color="blue">researching</font>,     developing and enhancing our <font color="blue">technology</font> and products and <font color="blue">establishing</font> our     sales, marketing and <font color="blue">administrative</font> <font color="blue">organizations</font> than we have generated in     revenues</td>
    </tr>
    <tr>
      <td>We expect that our operating <font color="blue">expenses will continue</font> to increase in     the <font color="blue"><font color="blue">foreseeable future</font> as</font> we increase our sales and <font color="blue">marketing <font color="blue">activities</font></font>,     expand our <font color="blue">operations</font> and continue to develop our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>It is possible     that we will not be able to achieve the <font color="blue">revenue levels</font> required to achieve     and sustain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We may need <font color="blue"><font color="blue">additional</font> capital</font>, which may be unavailable</td>
    </tr>
    <tr>
      <td>The  <font color="blue">commercialization</font>  of  our  current  <font color="blue">product line</font>, <font color="blue">acquisition</font> of     complimentary <font color="blue">technologies</font> and the <font color="blue">development</font> and <font color="blue">commercialization</font> of any     <font color="blue">additional</font> <font color="blue">products may</font> require <font color="blue">greater expenditures than</font> expected in our     current business plan</td>
    </tr>
    <tr>
      <td>Our capital <font color="blue">requirements</font> will depend on numerous     factors, including:           •   our rate of sales growth—fast growth may actually increase our need     for <font color="blue"><font color="blue">additional</font> capital</font> to hire <font color="blue">additional</font> staff, purchase <font color="blue">additional</font>     inventory, and finance the increase in <font color="blue">accounts receivable</font>;           •   our progress in marketing-related clinical evaluations and product     <font color="blue">development</font> programs, all of which will require <font color="blue"><font color="blue">additional</font> capital</font>;           •   our receipt of, and the time required to obtain, <font color="blue">regulatory</font> clearances     and approvals—the longer <font color="blue">regulatory</font> approval takes, the more working capital     we will need to support our <font color="blue">regulatory</font> and <font color="blue"><font color="blue">development</font> efforts</font> in advance of     sales;           •   the level of resources that we devote to the <font color="blue">development</font>, manufacture     and marketing of our products—any decision we make to improve, expand,     acquire complimentary <font color="blue">technologies</font> or simply change our process, products or     <font color="blue">technology</font> will require <font color="blue">increased funds</font>;                                           20     ______________________________________________________________________         •   <font color="blue">facilities</font> <font color="blue">requirements</font>—as we grow we need <font color="blue">additional</font> <font color="blue">manufacturing</font>,     <font color="blue">warehousing</font> and administration <font color="blue">facilities</font> and the costs of the <font color="blue">facilities</font>     will be borne before substantially increased revenue from growth would     occur;           •   <font color="blue">market <font color="blue">acceptance</font></font> and demand for our products—although growth may     increase our capital needs, the lack of growth and <font color="blue">continued losses</font> would     <font color="blue">also increase</font> our need for capital;           •   customer financing strategies—our attempt to <font color="blue">accelerate</font> the purchasing     <font color="blue">processes by offering internal leasing programs as</font> an <font color="blue">alternative</font> to     <font color="blue">outright purchasing</font> and by providing purchasers with extended payment terms     and financing options will consume <font color="blue"><font color="blue">additional</font> capital</font>; and           •   large electrode contracts—we intend to <font color="blue">bid on several</font> large electrode     <font color="blue">manufacturing</font> contracts, any one of which, if <font color="blue">awarded would</font> require     substantial <font color="blue">capital investment</font> in <font color="blue">equipment at</font> our Vermed division</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">predict accurately</font> the timing and amount of our capital     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">raise <font color="blue">additional</font> funds through public</font> or     private  financing,  bank  loans, collaborative <font color="blue">relationships</font> or other     <font color="blue"><font color="blue">arrangements</font> earlier than</font> expected</td>
    </tr>
    <tr>
      <td>It is possible that banks, venture     <font color="blue">capitalists</font> and other <font color="blue">investors may</font> perceive our <font color="blue">capital structure</font>, our     history  of losses or the need to achieve <font color="blue">widespread <font color="blue">acceptance</font></font> of our     <font color="blue">technology</font> as too great a risk to bear</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">additional</font> funding may     not  be  available at attractive terms, or at all</td>
    </tr>
    <tr>
      <td>If we cannot obtain     <font color="blue"><font color="blue">additional</font> capital</font> when needed, we may be forced to agree to <font color="blue">unattractive</font>     financing  terms,  to change our method of operation or to curtail our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may default on</font> our credit <font color="blue"><font color="blue">agreement</font>s</font> and have to <font color="blue">immediately repay</font> all     <font color="blue">amounts outstanding</font></td>
    </tr>
    <tr>
      <td>Our credit <font color="blue"><font color="blue">agreement</font> contains certain</font> reporting, <font color="blue">profitability</font> and liquidity     <font color="blue">covenants which</font> if not met, could result in an event of <font color="blue">default under</font> the     credit <font color="blue"><font color="blue">agreement</font> under which</font> the <font color="blue">lenders could elect</font> to declare all amounts     <font color="blue">outstanding under</font> the credit <font color="blue">agreement</font>, together with accrued interest, to     be <font color="blue">immediately due</font> and payable</td>
    </tr>
    <tr>
      <td>If we were unable to repay those amounts,     the <font color="blue">lenders could proceed against</font> the <font color="blue">collateral guaranteed</font> to them to     secure  such  <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>In  addition, the operating and financial     <font color="blue">restrictions</font> and covenants in our credit <font color="blue">agreement</font>, and any <font color="blue">future financing</font>     <font color="blue"><font color="blue">agreement</font>s</font> may adversely affect our ability to finance future <font color="blue">operations</font> and     meet our capital needs</td>
    </tr>
    <tr>
      <td>Our current credit <font color="blue">agreement</font> restricts our ability     to incur <font color="blue">additional</font> <font color="blue">indebtedness</font>, create liens, sell assets, make certain     <font color="blue">investments</font>,  pay  dividends  or make <font color="blue">distribution</font>s, repurchase equity     interests, redeem subordinated <font color="blue">indebtedness</font>, enter into certain <font color="blue">transaction</font>s     <font color="blue">with affiliates</font>, or <font color="blue">enter into mergers</font> or <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">manage growth successfully</font></td>
    </tr>
    <tr>
      <td>If successful, we will experience a period of growth that could place a     <font color="blue">significant</font> strain upon our managerial, financial and <font color="blue">operational resources</font></td>
    </tr>
    <tr>
      <td>Our infrastructure, procedures, controls and information <font color="blue">systems may</font> not be     adequate  to support our <font color="blue">operations</font> and to achieve the <font color="blue">rapid execution</font>     <font color="blue">necessary</font> to <font color="blue">successfully market</font> our products</td>
    </tr>
    <tr>
      <td>Our future operating results     <font color="blue">will also depend on</font> our ability to <font color="blue">continually upgrade</font> our information     systems, expand our <font color="blue">direct sales force</font> and our internal sales, marketing and     <font color="blue">support staff</font></td>
    </tr>
    <tr>
      <td>If we are unable to manage future expansion <font color="blue"><font color="blue">effective</font>ly</font>, our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> will suffer, our     <font color="blue">senior management will</font> be less <font color="blue">effective</font>, and our revenues and product     <font color="blue"><font color="blue">development</font> efforts</font> may decrease</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">international</font> sales expose us</font> to <font color="blue">unique risks</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">international</font> sales could represent a <font color="blue">meaningful</font>     portion of our revenue in the future</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">regional <font color="blue">distributors</font></font> and     GEMS-IT to assist us with our <font color="blue">international</font> sales efforts</td>
    </tr>
    <tr>
      <td>In June of 2004,     we purchased 80prca of the <font color="blue">outstanding <font color="blue">common stock</font></font> of Medis, which is located     in Ilmenau, Germany</td>
    </tr>
    <tr>
      <td>As such, we are exposed to risks from <font color="blue">international</font>     sales, which include unexpected changes in <font color="blue">regulatory</font> <font color="blue">requirements</font>, tariffs     and other barriers and <font color="blue">restrictions</font> and <font color="blue">reduced protection</font> for <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">fluctuations</font> in the rates of <font color="blue">exchange may</font> subject     us to foreign currency losses related to the Medis deferred <font color="blue">acquisition</font>     payments  or increase the price in <font color="blue">local currencies</font> of our products in     foreign  markets  and make our <font color="blue">products relatively</font> more <font color="blue">expensive than</font>     <font color="blue">competitive products</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       We may not receive <font color="blue">approvals by foreign regulators</font> that are <font color="blue">necessary</font> for     <font color="blue">international</font> sales</td>
    </tr>
    <tr>
      <td>Sales of medical devices outside <font color="blue">the United States </font>are subject to foreign     <font color="blue">regulatory</font> <font color="blue">requirements</font> that <font color="blue">vary from country</font> to country</td>
    </tr>
    <tr>
      <td>If we or our     inter<font color="blue">national <font color="blue">distributors</font></font> fail to obtain or maintain required pre-market     approvals or fail to <font color="blue">comply with</font> foreign <font color="blue">regulations</font>, foreign <font color="blue">regulatory</font>     <font color="blue">authorities may</font> require us to file revised <font color="blue">government</font>al notifications, cease     <font color="blue"><font color="blue">commercial sale</font>s</font> of our products in the <font color="blue">applicable countries</font> or otherwise     cure the problem</td>
    </tr>
    <tr>
      <td>Such enforcement action by <font color="blue">regulatory</font> <font color="blue">authorities may</font> be     costly</td>
    </tr>
    <tr>
      <td>In order to sell our <font color="blue">products within</font> the European <font color="blue">community</font>, we must     comply  with the European <font color="blue">community</font>’s medical device directive</td>
    </tr>
    <tr>
      <td><font color="blue">The CE     </font>marking  on our <font color="blue">products attests</font> to this compliance</td>
    </tr>
    <tr>
      <td>Future <font color="blue">regulatory</font>     changes may limit our ability to use the CE mark, and any <font color="blue">new products</font> we     develop may not qualify for the CE mark</td>
    </tr>
    <tr>
      <td>If we lose this <font color="blue">authorization</font> or     fail to obtain <font color="blue">authorization</font> on future products, we will not be able to sell     our products in the European <font color="blue">community</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results <font color="blue">frequently vary due</font> to <font color="blue">factors outside</font> our     control</td>
    </tr>
    <tr>
      <td>We have experienced and expect to continue to experience <font color="blue">fluctuations</font> in     quarterly operating results due to a number of factors</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font>     many of these factors, which include the following:           •   the timing and number of new product <font color="blue"><font color="blue">introduction</font>s</font>;           •   the number of <font color="blue">selling days</font> in a <font color="blue">given quarter</font>;           •   the mix of sales of higher and <font color="blue">lower margin products</font> in a quarter;           •   the <font color="blue">market <font color="blue">acceptance</font></font> of, and changes in demand for our products;           •   the impact of any changes in <font color="blue"><font color="blue">generally</font> accepted</font> <font color="blue">accounting</font> principles;           •   the loss of any of our <font color="blue">key <font color="blue">distributors</font></font>;           •   the impact of <font color="blue"><font color="blue">acquisition</font>s</font>, divestitures, strategic alliances, and     other <font color="blue">significant</font> corporate events;           •   <font color="blue">development</font> and <font color="blue">promotional expenses</font> relating to the <font color="blue">introduction</font> of     <font color="blue">new products</font> or <font color="blue">enhancements</font> of <font color="blue">existing products</font>;           •   <font color="blue">product returns</font> or bad debt write-offs;           •   changes in <font color="blue">pricing policies by</font> our <font color="blue">competitors</font>;           •   the timing of <font color="blue">regulatory</font> compliance audits;           •   the impact of weather related <font color="blue">disasters such as hurricane</font> Katrina;           •   the timing of orders from major customers and <font color="blue">distributors</font>;           •   delays in shipment of products or <font color="blue">components</font> to us by our vendors; and           •   The timing of <font color="blue">customer orders</font> and shipments</td>
    </tr>
    <tr>
      <td>Our <font color="blue">quarterly sales</font> have     reflected a pattern in which a <font color="blue">disproportionate percentage</font> of our total     <font color="blue">quarterly sales</font> occur toward the end of each of our <font color="blue">fiscal quarters</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">uneven sales pattern</font> makes prediction of revenue, earnings and working     capital for each financial period <font color="blue">difficult</font>, increases the risk of     <font color="blue">unanticipated</font> <font color="blue">variations</font> in quarterly results and <font color="blue">financial condition</font> and     <font color="blue">places pressure on</font> our inventory management, staffing, and logistics     systems</td>
    </tr>
    <tr>
      <td>Accordingly, you should not rely on period-to-period comparisons of our     financial results <font color="blue">as indications</font> of future results</td>
    </tr>
    <tr>
      <td>We depend on <font color="blue">third parties</font> for <font color="blue">development</font> and <font color="blue">manufacturing</font> services</td>
    </tr>
    <tr>
      <td>Our strategy for <font color="blue">development</font> and <font color="blue">commercialization</font> of some of our products     depends upon entering into various <font color="blue">arrangements</font> with <font color="blue">third parties</font> and upon     the <font color="blue">subsequent success</font> of these parties in performing their <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>We     may not be able to negotiate acceptable <font color="blue">arrangements</font> in the future, and our     existing  <font color="blue">arrangements</font>  may  not  be successful</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on contracted</font>     engineering services, particularly from Rivertek</td>
    </tr>
    <tr>
      <td>Also, we currently                                           22     ______________________________________________________________________       assemble our products from <font color="blue">components</font> manufactured by a limited number of     <font color="blue">manufacturers</font></td>
    </tr>
    <tr>
      <td>Therefore, we are <font color="blue">dependent on</font> component and <font color="blue">subassembly</font>     <font color="blue">manufacturers</font></td>
    </tr>
    <tr>
      <td>If we experience a termination, modification or <font color="blue">disruption</font> of     any of our <font color="blue">development</font> or <font color="blue">manufacturing</font> <font color="blue">arrangements</font>, we may be unable to     deliver products to our <font color="blue">customers on</font> a timely basis, which may lead to     <font color="blue">customer dissatisfaction</font> and damage to our reputation</td>
    </tr>
    <tr>
      <td>Our limited order backlog makes it <font color="blue">difficult</font> to <font color="blue">predict sales</font> and plan     <font color="blue">manufacturing</font>  <font color="blue">requirements</font>,  which can lead to lower revenues, higher     expenses and <font color="blue">reduced margins</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">customers typically</font> order <font color="blue">products on</font> a purchase order basis, and we do     not <font color="blue">generally</font> have long-term purchase contracts</td>
    </tr>
    <tr>
      <td>In limited <font color="blue">circumstances</font>,     <font color="blue">customer orders</font> may be cancelled, changed or <font color="blue">delayed on</font> short notice</td>
    </tr>
    <tr>
      <td><font color="blue">Lack     </font>of <font color="blue">significant</font> order backlog makes it <font color="blue">difficult</font> for us to forecast future     sales  with <font color="blue">certainty</font></td>
    </tr>
    <tr>
      <td>Varying <font color="blue">sales cycles with</font> our customers make it     <font color="blue">difficult</font> to <font color="blue">accurately forecast</font> component and product <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">factors expose us</font> to a number of risks:           •   If we <font color="blue">overestimate</font> our <font color="blue">requirements</font> we may be obligated to purchase     more <font color="blue">components</font> or third-party products than is required;           •   If we underestimate our <font color="blue">requirements</font>, our third-party <font color="blue">manufacturers</font>     and <font color="blue">suppliers may</font> have an inadequate product or product component inventory,     <font color="blue">which could</font> interrupt <font color="blue">manufacturing</font> of our products and result in delays in     shipments and revenues;           •   We may also experience shortages of product <font color="blue">components</font> from time to     time, <font color="blue">which also could delay</font> the <font color="blue">manufacturing</font> of our products; and           •   Over or under production can lead to higher expense, lower than     anticipated revenues, and <font color="blue">reduced margins</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is subject to <font color="blue">price volatility</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has been and is likely to continue to     be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price could</font> be subject to wide <font color="blue">fluctuations</font> in     response to <font color="blue">various factors beyond</font> our control, including:           •   actual or anticipated quarterly <font color="blue">variations</font> in operating results;           •   <font color="blue">announcements</font> of technological innovations, <font color="blue">new products</font> or <font color="blue">pricing by</font>     our <font color="blue">competitors</font>;           •   changes in, or failure to meet, financial estimates of securities     analysts;           •   the rate of <font color="blue">adoption by physicians</font> of ICG <font color="blue">technology</font> in targeted     markets;           •   the timing and extent of technological advancements, patent and     <font color="blue">regulatory</font> approvals;           •   the impact of <font color="blue"><font color="blue">acquisition</font>s</font>, divestitures, strategic alliances, and     other <font color="blue">significant</font> corporate events;           •   anything other <font color="blue">than unqualified</font> reports by our <font color="blue">outside auditors</font>;           •   results of <font color="blue">clinical studies</font>;           •   changes in <font color="blue">reimbursement</font> policies of third-party payers;           •   the sales of our <font color="blue">common stock</font> by affiliates or other <font color="blue">shareholders with</font>     large holdings; and           •   <font color="blue">general economic</font> and <font color="blue">market <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td>Our future operating results may fall below the <font color="blue">expectations</font> of securities     industry  analysts  or investors</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such shortfall could</font> result in a     <font color="blue">significant</font> decline in the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition,     the stock market has at times experienced <font color="blue">significant</font> price and volume     <font color="blue">fluctuations</font> that have affected the <font color="blue">market price</font>s of the stock of many     medical device companies that often have <font color="blue">been unrelated</font> to the operating     performance of <font color="blue">such companies</font></td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may directly     influence the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       We may not continue to receive <font color="blue">necessary</font> FDA or other <font color="blue">regulatory</font> clearances     or approvals</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">activities</font> are subject to extensive, <font color="blue">ongoing regulation by</font>     the <font color="blue">Food and Drug Administration </font>and other <font color="blue">government</font>al authorities</td>
    </tr>
    <tr>
      <td><font color="blue">Delays     </font>in receipt of, or failure to obtain or maintain, <font color="blue">regulatory</font> clearances and     approvals, or any failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font>, could     delay or prevent our ability to market or distribute our <font color="blue">product line</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">product <font color="blue">liability</font></font> claims and <font color="blue">product recalls</font> that may not     be <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td>The nature of our business <font color="blue">exposes us</font> to risks of <font color="blue">product <font color="blue">liability</font></font> claims     and  product  recalls</td>
    </tr>
    <tr>
      <td><font color="blue">Medical  </font><font color="blue">devices as complex as ours frequently</font>     experience errors or failures, especially when <font color="blue">first introduced</font> or when new     versions are released</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">sometimes used</font> in procedures where     there is a high risk of <font color="blue">serious injury</font> or death</td>
    </tr>
    <tr>
      <td>These risks will exist even     <font color="blue">with respect</font> to those products that have received, or may in the future     receive, <font color="blue">regulatory</font> clearance for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We did not carry <font color="blue">product <font color="blue">liability</font></font> insurance during some periods before     May 15, 1995</td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">product <font color="blue">liability</font></font> insurance, however our     <font color="blue">product <font color="blue">liability</font></font> insurance may not be adequate</td>
    </tr>
    <tr>
      <td>In the future, insurance     coverage may not be available on <font color="blue">commercially</font> reasonable terms, or at all</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">product <font color="blue">liability</font></font> claims or <font color="blue">product recalls</font> could damage our     <font color="blue">reputation even</font> if we have <font color="blue">adequate insurance coverage</font></td>
    </tr>
    <tr>
      <td>A low <font color="blue">stock price could</font> result in our being de-listed from the <font color="blue">NASDAQ Market     </font>and subject us to <font color="blue">regulations</font> that could reduce our ability to raise funds</td>
    </tr>
    <tr>
      <td>If our stock price were to drop below dlra1dtta00 per share and remain below dlra1dtta00     per share for an <font color="blue">extended period</font> of time, or if we fail to maintain other     NASDAQ  criteria,  NASDAQ may de-list our <font color="blue">common stock</font> from the Nasdaq     National  Market</td>
    </tr>
    <tr>
      <td>In such an event, our <font color="blue">shares could only</font> be traded on     over-the-counter  bulletin  <font color="blue">board system</font></td>
    </tr>
    <tr>
      <td>This method of <font color="blue">trading could</font>     <font color="blue">significant</font>ly impair our ability to <font color="blue">raise new capital</font></td>
    </tr>
    <tr>
      <td>In the event that our <font color="blue">common stock</font> was de-listed from the Nasdaq National     Market due to <font color="blue">low stock price</font>, we may become subject to <font color="blue">special rules</font>,     <font color="blue">called penny stock rules</font> that impose <font color="blue">additional</font> sales practice <font color="blue">requirements</font>     on broker-dealers who sell our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The rules require, among other     things, the delivery, prior to the <font color="blue">transaction</font>, of a <font color="blue">disclosure</font> schedule     required  by  the  SEC  relating  to  the market for <font color="blue">penny stocks</font></td>
    </tr>
    <tr>
      <td>The     broker-dealer  also  must disclose the <font color="blue">commissions payable both</font> to the     broker-dealer and the <font color="blue">registered representative</font> and <font color="blue">current quotations</font> for     the securities, and <font color="blue">monthly statements must</font> be sent disclosing <font color="blue">recent price</font>     information</td>
    </tr>
    <tr>
      <td>In the event that our <font color="blue">common stock</font> becomes <font color="blue">characterized</font> as a penny stock,     our market liquidity could be severely affected</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulations</font> relating to     <font color="blue">penny stocks</font> could limit the ability of broker-dealers to sell our common     stock and thus the ability of purchasers in this offering to sell their     <font color="blue">common stock</font> in the <font color="blue">secondary market</font></td>
    </tr>
    <tr>
      <td><font color="blue">Corporate </font>scandals involving <font color="blue">accounting</font> <font color="blue">irregularities</font> have resulted in     un<font color="blue">availability</font> of or <font color="blue">significant</font>ly higher premiums for director and officer     <font color="blue"><font color="blue">liability</font> insurance</font></td>
    </tr>
    <tr>
      <td>As  a  result of well-publicized corporate business failures involving     improper acts by <font color="blue">executives</font> and <font color="blue">accounting</font> <font color="blue">irregularities</font>, director and     officer <font color="blue"><font color="blue">liability</font> insurance</font> has become more <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>If we are     unable to obtain <font color="blue">sufficient director</font> and officer <font color="blue"><font color="blue">liability</font> insurance</font> at     rates that are reasonable or at all or if the <font color="blue">possibility</font> of director and     officer <font color="blue">liability</font> is expanded by <font color="blue">regulatory</font> or judicial <font color="blue">development</font>s, we may     not  be  able  to retain our <font color="blue">current officers</font> and <font color="blue">directors</font> or attract     qualified <font color="blue">directors</font> and officers in the future</td>
    </tr>
    <tr>
      <td>We do not know the effects of <font color="blue"><font color="blue">healthcare reform</font> proposals</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">healthcare industry</font> is <font color="blue">undergoing fundamental</font> changes resulting from     political,  economic  and <font color="blue">regulatory</font> influences</td>
    </tr>
    <tr>
      <td>In the United States,     <font color="blue">comprehensive programs</font> have been suggested that <font color="blue">would increase</font>                                           24     ______________________________________________________________________       access to healthcare for the uninsured, control the <font color="blue">escalation</font> of healthcare     <font color="blue">expenditures within</font> the economy and use healthcare <font color="blue">reimbursement</font> policies to     balance the <font color="blue">federal budget</font></td>
    </tr>
    <tr>
      <td>We expect that the US Congress and state <font color="blue">legislatures</font> will continue to     review and assess various <font color="blue"><font color="blue">healthcare reform</font> proposals</font>, and public debate of     these issues <font color="blue">will likely</font> continue</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict which</font>, if any, of such     <font color="blue">reform proposals will</font> be adopted and when they might be <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font><font color="blue">countries also</font> are considering <font color="blue">healthcare reform</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>changes in     <font color="blue">healthcare systems could</font> have a substantial <font color="blue">impact on</font> the manner in which we     conduct our business and could require us to revise our strategies</td>
    </tr>
    <tr>
      <td>We do not intend to <font color="blue">pay dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We  do not intend to pay any <font color="blue">cash dividends on</font> our <font color="blue">common stock</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
  </tbody>
</table>